Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase 2 Study of LY2495655 in Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy
2011-003822-29Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pancreatic cancer (PC), cancer anorexia-cachexia syndrome (CACS) and muscle atrophy comparing LY2495655 + gemcitabine-based chemotherapy with Placebo + gemcitabine-based chemotherapy (2 arms). Primary endpoint: Overall survival. Started Mar 2012; status: completed.
02
Drugs
landogrozumab
03
Conditions
pancreatic cancer (PC)cancer anorexia-cachexia syndrome (CACS)muscle atrophy
Beyond the preview
Go deeper on 2011-003822-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003822-29.